Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Biogen, with 18 buy, 13 hold, one sell and one strong-buy rating among 33 firms. The average 12-month price target is $227.07, above the reported share price of $214.35.
• Biogen exceeded quarterly expectations, reporting $3.60 EPS versus a $2.94 consensus and revenue of $2.74 billion versus $2.46 billion expected. Revenue increased 3.4% year over year, and management provided fiscal 2026 EPS guidance of $12.00–$13.00.
• Institutional investors own 87.93% of Biogen’s stock, while several firms recently increased their holdings. The shares have traded between $131.52 and $222.15 over the past year and are currently near that range’s upper end.

Shares of Biogen Inc. (NASDAQ:BIIB - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirty-three research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $227.0714.

Several research analysts have recently issued reports on BIIB shares. TD Cowen increased their price target on Biogen from $215.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Oppenheimer reaffirmed an "outperform" rating and issued a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. Morgan Stanley increased their target price on shares of Biogen from $222.00 to $231.00 and gave the company an "equal weight" rating in a research report on Thursday, July 30th. Zacks Research raised shares of Biogen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Finally, Piper Sandler restated an "overweight" rating on shares of Biogen in a research report on Tuesday, July 14th.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Rothschild Investment LLC lifted its holdings in Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company's stock worth $90,000 after buying an additional 56 shares during the period. Wedbush Securities Inc. increased its stake in shares of Biogen by 5.1% in the second quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock valued at $251,000 after buying an additional 56 shares during the period. Meeder Advisory Services Inc. increased its stake in shares of Biogen by 1.2% in the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock valued at $866,000 after buying an additional 57 shares during the period. Kera Capital Partners Inc. raised its position in shares of Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 58 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company's stock worth $801,000 after acquiring an additional 65 shares during the period. Institutional investors own 87.93% of the company's stock.

Biogen Stock Performance

BIIB opened at $214.35 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The business's 50 day moving average is $205.20 and its 200-day moving average is $194.32. The stock has a market cap of $31.67 billion, a PE ratio of 37.94, a price-to-earnings-growth ratio of 6.90 and a beta of 0.17. Biogen has a twelve month low of $131.52 and a twelve month high of $222.15.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, analysts predict that Biogen will post 12.39 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source